← Holders
Squadron Capital Management LLC
What Squadron Capital Management LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2050709 · Filed Nov 16, 2026
- Positions
- 45
- Reported value
- $398.5M
- Opened
- 21
- Closed
- 19
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Dec 31, 2025$236M33 positions
- Mar 31, 2026$272.9M37 positions
- Jun 30, 2026$322.2M43 positions
- Sep 30, 2026$398.5M45 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
KODKodiak Sciences Inc. | 420K | −16.0% | $39.8M | 10% |
CCCCC4 Therapeutics, Inc. | 9.3M | +29.4% | $31M | 7.8% |
COGTCogent Biosciences, Inc. | 915K | +5.8% | $29.3M | 7.4% |
| 270K | New | $25.6M | 6.4% | |
SLNSilence Therapeutics plc | 2.1M | New | $22.8M | 5.7% |
ZNTLZentalis Pharmaceuticals, Inc. | 6.8M | +84.5% | $18.9M | 4.7% |
EWTXEdgewise Therapeutics, Inc. | 425K | +46.6% | $17.3M | 4.3% |
RLAYRelay Therapeutics, Inc. | 785K | −19.1% | $14.2M | 3.6% |
ORICOric Pharmaceuticals, Inc. | 1M | New | $13.5M | 3.4% |
RLMDRelmada Therapeutics, Inc. | 3.5M | −52.4% | $13.2M | 3.3% |
DFTXDefinium Therapeutics, Inc. | 340K | +300.0% | $12.9M | 3.2% |
PHVSPharvaris N.V. | 400K | New | $12.7M | 3.2% |
ANLAdlai Nortye Group Ltd. | 764.9K | ±0% | $12.2M | 3.1% |
VERAVera Therapeutics, Inc. | 305K | New | $9.8M | 2.5% |
IVAInventiva S.A. | 2.4M | −1.4% | $8.9M | 2.2% |
| 134.5K | +348.3% | $8.8M | 2.2% | |
| 265K | New | $8.5M | 2.1% | |
AVTXAvalo Therapeutics, Inc. | 450K | New | $6.9M | 1.7% |
ACRSAclaris Therapeutics, Inc. | 1.2M | New | $6.3M | 1.6% |
| 1.3M | +47.1% | $5.5M | 1.4% | |
ASMBAssembly Biosciences, Inc. | 225K | +40.6% | $5.3M | 1.3% |
ADAGAdagene Inc. | 1.6M | +29.3% | $5.2M | 1.3% |
CBIOCrescent Biopharma, Inc. | 350K | New | $5.1M | 1.3% |
YARWYarrow Bioscience, Inc. | 225K | New | $5.1M | 1.3% |
ZURAZura Bio Ltd | 1.2M | New | $5M | 1.3% |
TCGXTCGX Acquisition Corp. | 370.2K | New | $4.6M | 1.2% |
CTNMContineum Therapeutics, Inc. | 323.6K | +24.5% | $4.3M | 1.1% |
| 142.5K | −22.1% | $4.3M | 1.1% | |
IKTInhibikase Therapeutics, Inc. | 2M | −33.3% | $4.1M | 1% |
PALIPalisade Bio, Inc. | 3M | ±0% | $4.1M | 1% |
TNGXTango Therapeutics, Inc. | 150K | New | $3.7M | 0.9% |
JANXJanux Therapeutics, Inc. | 215K | New | $3.7M | 0.9% |
SVRASavara Inc | 675K | New | $3.5M | 0.9% |
| 225K | New | $3M | 0.8% | |
IRLAIRulya Therapeutics Inc. | 90K | +122.9% | $2.8M | 0.7% |
JTTTJATT III Acquisition Corp | 250K | New | $2.8M | 0.7% |
SCYXScynexis Inc | 515K | −32.0% | $2.5M | 0.6% |
| 180K | New | $2M | 0.5% | |
ALXOALX Oncology Holdings Inc | 1.4M | New | $1.9M | 0.5% |
LPCNLipocine Inc. | 810K | ±0% | $1.8M | 0.4% |
| 250K | ±0% | $1.8M | 0.4% | |
PEPGPepGen Inc. | 600K | New | $1.5M | 0.4% |
| 400K | ±0% | $1.3M | 0.3% | |
JATTJATT II Acquisition Corp. | 65K | New | $730.9K | 0.2% |
| 100K | −76.5% | $277K | 0.1% |